How do analysts assess whether a deferred tax asset is realizable?

DTA realizability assessment is a critical area for financial analysts because management has significant judgment in deciding whether to recognize or write down deferred tax assets. The valuation allowance directly affects reported net income.

The Standard (ASC 740 / IAS 12):

A DTA is recognized to the extent it is 'more likely than not' (>50% probability under US GAAP) or 'probable' (under IFRS) that sufficient taxable income will exist to utilize the deduction. If not, a valuation allowance reduces the DTA.

Positive Evidence (supports realization):

1. Existing taxable temporary differences that will reverse and generate taxable income in the same period the DTA reverses
2. History of profitable operations — consistent pre-tax profits in recent years
3. Backlog or contracted future income — signed contracts that will produce taxable income
4. Tax planning strategies — legal actions the company can take to generate taxable income (e.g., selling appreciated assets, accelerating income)
5. Strong order pipeline with high conversion probability

Negative Evidence (challenges realization):

1. Cumulative losses in recent years — typically a 3-year lookback showing pre-tax losses
2. History of DTA expiration — prior NOL carryforwards that expired unused
3. Expected future losses from operations or restructuring
4. Unsettled circumstances that could cause losses (litigation, regulatory changes)
5. Brief carryforward period remaining before the DTA expires

Analyst Framework:

Example: Pemberton Biotech has a $12 million DTA primarily from NOL carryforwards expiring in 7 years. The company had losses in 3 of the last 4 years but recently won FDA approval for a key drug. Management recognized the full DTA with no valuation allowance.

As an analyst, you should:

1. Question the optimism. Cumulative losses are strong negative evidence under ASC 740.
2. Check revenue projections. Does the approved drug generate enough taxable income within 7 years to use the NOLs?
3. Compare to peers. Do similar biotech companies with recent approvals carry full DTAs?
4. Monitor changes. A sudden release of valuation allowance can inflate earnings by the full amount in a single quarter.

Earnings quality impact: A company that recognizes a large DTA without sufficient evidence may be overstating assets and understating tax expense. Conversely, releasing a valuation allowance generates a one-time earnings boost that does not reflect operating performance.

For more on deferred tax analysis, explore our CFA Level II FRA course materials.